Urinary monocyte chemotactic protein 1: Marker of renal function decline in diabetic and nondiabetic proteinuric renal disease

Journal of Nephrology

Volumn 24, Issue 1, 2011, Pages 60-67

  Camilla, Roberta ^a   Brachemi, Soumeya ^b   Pichette, Vincent ^c   Cartier, Pierre ^b   Laforest Renald, Alexandra ^a   MacRae, Tara ^a   Madore, François ^a   Troyanov, Stéphan ^a  

^a HÔPITAL DU SACRÉ COEUR DE MONTRÉAL   (Canada)

^b CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^c MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

Author keywords

Monocyte chemotactic protein 1; Proteinuria; Rate of renal function decline; Transforming growth factor beta 1; Urinary biomarkers

Indexed keywords

CREATININE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; MONOCYTE CHEMOTACTIC PROTEIN 1; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID; TRANSFORMING GROWTH FACTOR BETA1;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CREATININE URINE LEVEL; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DISEASE COURSE; DISEASE MARKER; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY DISEASE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; PROTEIN URINE LEVEL; PROTEINURIA; RECEIVER OPERATING CHARACTERISTIC; REPRODUCIBILITY; RETROSPECTIVE STUDY; RISK ASSESSMENT;

EID: 78651103899     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: 10.5301/JN.2010.1458     Document Type: Article

References (38)

1. Cattran DC, Reich HN, Beanlands HJ, Miller JA, Scholey JW, Troyanov S. The impact of sex in primary glomerulonephritis. Nephrol Dial Transplant. 2008;23:2247-2253.
2. Schrijvers BF, De Vriese AS, Flyvbjerg A. From hyperglycemia to diabetic kidney disease: the role of metabolic, hemodynamic, intracellular factors and growth factors/cytokines. Endocr Rev. 2004;25:971-1010.
3. Segerer S, Nelson PJ, Schlondorff D. Chemokines, chemokine receptors, and renal disease: from basic science to pathophysiologic and therapeutic studies. J Am Soc Nephrol. 2000;11:152-176.
4. Hirschberg R, Wang S. Proteinuria and growth factors in the development of tubulointerstitial injury and scarring in kidney disease. Curr Opin Nephrol Hypertens. 2005;14:43-52.
5. Wada T, Yokoyama H, Furuichi K, et al. Intervention of crescentic glomerulonephritis by antibodies to monocyte chemotactic and activating factor (MCAF/MCP-1). FASEB J. 1996;10:1418-1425.
6. Huang Y, Wongamorntham S, Kasting J, et al. Renin increases mesangial cell transforming growth factor-beta1 and matrix proteins through receptor-mediated, angiotensin II-independent mechanisms. Kidney Int. 2006;69:105-113.
7. Rovin BH, Song H, Birmingham DJ, Hebert LA, Yu CY, Nagaraja HN. Urine chemokines as biomarkers of human systemic lupus erythematosus activity. J Am Soc Nephrol. 2005;16:467-473.
8. Tesch GH. MCP-1/CCL2: a new diagnostic marker and therapeutic target for progressive renal injury in diabetic nephropathy. Am J Physiol Renal Physiol. 2008;294:F697-F701.
9. Goumenos DS, Tsamandas AC, Oldroyd S, et al. Transforming growth factor-beta(1) and myofibroblasts: a potential pathway towards renal scarring in human glomerular disease. Nephron. 2001;87:240-248.
10. De Muro P, Faedda R, Fresu P, et al. Urinary transforming growth factor-beta 1 in various types of nephropathy. Pharmacol Res. 2004;49:293-298.
11. Rovin BH, Doe N, Tan LC. Monocyte chemoattractant protein-1 levels in patients with glomerular disease. Am J Kidney Dis. 1996;27:640-646.
12. Wada T, Yokoyama H, Su SB, et al. Monitoring urinary levels of monocyte chemotactic and activating factor reflects disease activity of lupus nephritis. Kidney Int. 1996;49:761-767.
13. Saitoh A, Suzuki Y, Takeda M, Kubota K, Itoh K, Tomino Y. Urinary levels of monocyte chemoattractant protein (MCP)-1 and disease activity in patients with IgA nephropathy. J Clin Lab Anal. 1998;12:1-5.
14. Torres DD, Rossini M, Manno C, et al. The ratio of epider mal growth factor to monocyte chemotactic peptide-1 in the urine predicts renal prognosis in IgA nephropathy. Kidney Int. 2008;73:327-333.
15. Katz MH. Multivariable analysis: a primer for readers of medical research. Ann Intern Med. 2003;138:644-650.
16. Collins AJ, Kasiske B, Herzog C, et al. Excerpts from the United States Renal Data System 2004 annual data report: atlas of end-stage renal disease in the United States. Am J Kidney Dis. 2005;45:A5-A7, S1-S280.
17. Zelmer JL. The economic burden of end-stage renal disease in Canada. Kidney Int. 2007;72:1122-1129.
18. Joyce AT, Iacoviello JM, Nag S, et al. End-stage renal disease-associated managed care costs among patients with and without diabetes. Diabetes Care. 2004;27:2829-2835.
19. Kunz R, Friedrich C, Wolbers M, Mann JF. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med. 2008;148:30-48.
20. Burgess E, Muirhead N, Rene de Cotret P, Chiu A, Pichette V, Tobe S. Supramaximal dose of candesartan in proteinuric renal disease. J Am Soc Nephrol. 2009;20:893-900.
21. Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med. 2008;358:2433-2446.
22. Ruggenenti P, Perna A, Loriga G, et al. Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial. Lancet. 2005;365:939-946.
23. Mann JF, Schmieder RE, McQueen M, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet. 2008;372:547-553.
24. Atkins RC, Briganti EM, Lewis JB, et al. Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy. Am J Kidney Dis. 2005;45:281-287.
25. Jafar TH, Stark PC, Schmid CH, et al. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med. 2003;139:244-252.
26. Chow FY, Nikolic-Paterson DJ, Ozols E, Atkins RC, Rollin BJ, Tesch GH. Monocyte chemoattractant protein-1 promotes the development of diabetic renal injury in streptozotocin-treated mice. Kidney Int. 2006;69:73-80.
27. Sharma K, Jin Y, Guo J, Ziyadeh FN. Neutralization of TGF-beta by anti-TGF-beta antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice. Diabetes. 1996;45:522-530.
28. Ziyadeh FN, Hoffman BB, Han DC, et al. Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice. Proc Natl Acad Sci U S A. 2000;97:8015-8020.
29. Eardley KS, Zehnder D, Quinkler M, et al. The relationship between albuminuria, MCP-1/CCL2, and interstitial macrophages in chronic kidney disease. Kidney Int. 2006;69:1189-1197.
30. Sharma K, Ziyadeh FN, Alzahabi B, et al. Increased renal production of transforming growth factor-beta1 in patients with type II diabetes. Diabetes. 1997;46:854-859.
31. Yamamoto T, Nakamura T, Noble NA, Ruoslahti E, Border WA. Expression of transforming growth factor beta is elevated in human and experimental diabetic nephropathy. Proc Natl Acad Sci U S A. 1993;90:1814-1818.
32. Morii T, Fujita H, Narita T, et al. Association of monocyte chemoattractant protein-1 with renal tubular damage in diabetic nephropathy. J Diabetes Complications. 2003;17:11-15.
33. Amann B, Tinzmann R, Angelkort B. ACE inhibitors improve diabetic nephropathy through suppression of renal MCP-1. Diabetes Care. 2003;26:2421-2425.
34. Wasilewska AM, Zoch-Zwierz WM. Transforming growth factor-beta1 in nephrotic syndrome treated with cyclosporine and ACE inhibitors. Pediatr Nephrol. 2004;19:1349-1353.
35. Tsakas S, Goumenos DS. Accurate measurement and clinical significance of urinary transforming growth factor-beta1. Am J Nephrol. 2006;26:186-193.
36. Agarwal R, Siva S, Dunn SR, Sharma K. Add-on angiotensin II receptor blockade lowers urinary transforming growth factor-beta levels. Am J Kidney Dis. 2002;39:486-492.
37. Morii T, Fujita H, Narita T, et al. Increased urinary excretion of monocyte chemoattractant protein-1 in proteinuric renal diseases. Ren Fail. 2003;25:439-444.
38. Lely AT, van der Kleij FG, Kistemaker TJ, et al. Impact of the preintervention rate of renal function decline on outcome of renoprotective intervention. Clin J Am Soc Nephrol. 2008;3:54-60.